Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 149 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers

Surufatinib Renal Impairment Study

NCT04755088
Conditions
Renal Impairment
Interventions
Surufatinib
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Tustin, California • Orlando, Florida
Conditions
Chronic Kidney Disease
Interventions
Placebo, AST-120
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
46
States / cities
Tuscaloosa, Alabama • Hot Springs, Arkansas • Bakersfield, California + 43 more
Conditions
Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
Interventions
Extended release niacin, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Miami, Florida
Conditions
Dyslipidemia, Renal Insufficiency
Interventions
ABT-335, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Gainesville, Florida • Miami, Florida • Minneapolis, Minnesota + 3 more
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
aldesleukin, recombinant interferon alfa, sargramostim
Biological
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Graft Rejection, Kidney Failure
Interventions
cyclosporine or tacrolimus, sirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Tampa, Florida • Rochester, Minnesota • New York, New York + 4 more
Conditions
Type 2 Diabetes, Chronic Kidney Disease
Interventions
Dulaglutide, Insulin glargine, Insulin lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Montgomery, Alabama • Azusa, California • Granada Hills, California + 39 more
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
Interventions
Azacitidine, Pevonedistat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Conditions
Moderate-severe Chronic Kidney Disease Not Treated With Dialysis, Diabetic Kidney Disease, HgbA1c Less Than 8.5
Interventions
Combined Aerobic and Resistance Exercise via videoconferencing
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
30 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Sacramento, California
Conditions
Cancer
Interventions
DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, assessment of therapy complications, evaluation of cancer risk factors
Genetic · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Renal Impairment, Healthy Volunteer
Interventions
Entinostat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Conditions
Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions
Valproic acid, Isotonic saline solution
Drug
Lead sponsor
Westat
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
San Francisco, California • Denver, Colorado • Dallas, Texas + 1 more
Conditions
Renal Impairment
Interventions
AGO178C
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Conditions
Renal Impairment
Interventions
Opemalirsen (AZD2373)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
AAA617, 68Ga-PSMA-11
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
Interventions
Tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Conditions
Kidney Diseases, Hyponatremia
Interventions
conivaptan hydrochloride
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Anaheim, California
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
beclomethasone dipropionate
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
5 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Renal Impairment
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
58
States / cities
Birmingham, Alabama • Peoria, Arizona • Sierra Vista, Arizona + 55 more
Conditions
Renal Impairment
Interventions
YM178
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 79 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Anaheim, California • Miami, Florida
Conditions
Lymphoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Cancer
Interventions
acyclovir, acyclovir sodium, valacyclovir
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Omaha, Nebraska + 3 more
Conditions
Hepatitis C, Chronic
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
12
States / cities
Birmingham, Alabama • Kansas City, Kansas • New Orleans, Louisiana + 9 more